CD34 and Bcl-2 As Predictors for the Efficacy of Neoadjuvant Chemotherapy in Cervical Cancer

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2021 Jan 4

PMID 33392721

Citations 2

Authors

Yun Lin

Zhi Li

Mubiao Liu

Haiyan Ye

Jianhui He

Jianguo Chen

Affiliations

Soon will be listed here.

Abstract

Background: Successful neoadjuvant chemotherapy (NACT) could improve the surgical resection rate and radical curability of patients with cervical cancer, but only a subset of patients benefits. Therefore, identifying predictive biomarkers are urgently needed. The aim of this study was to evaluate the predictive value of CD34 and Bcl-2 in the NACT effectiveness of cervical cancer.

Methods: Sixty-seven patients with locally advanced cervical cancer (FIGO stages IB3, IIA2 or IIB) were classified into two groups based on effective (n = 48) and ineffective (n = 19) response to NACT. Immunohistochemistry was employed to identify CD34 and Bcl-2 expression before and after NACT. We analyzed the associations between the pre-NACT expression of these two biomarkers and the response of NACT. The expression of these two biomarkers before and after NACT was also assessed and compared.

Results: More patients were CD34 positive expression before NACT in effective group compared to ineffective group (p = 0.005). However, no statistically significant difference in Bcl-2 expression before NACT were found between two groups (p = 0.084). In NACT effective group, the expression of both CD34 and Bcl-2 after NACT are down-regulated (p < 0.001 and p < 0.001, respectively), while there are no statistical differences between the pre- and post-NACT expression of CD34 and Bcl-2 in NACT ineffective group (p = 0.453 and p = 0.317, respectively).

Conclusion: The positive CD34 expression before NACT may serve as a predictive biomarker for NACT of cervical cancer, but the pre-NACT expression of Bcl-2 is not an independent predictor. The down-regulated expression of these two indicators after NACT may indicate effective NACT.

Citing Articles

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden.

Dai M, Sheng J, Zhang Q, Wang J, Fu Q, Liang T Front Oncol. 2023; 13:1118633.

PMID: 36937383 PMC: 10016350. DOI: 10.3389/fonc.2023.1118633.

Comprehensive analysis of novel prognosis-related proteomic signature effectively improve risk stratification and precision treatment for patients with cervical cancer.

Ji X, Chu G, Chen Y, Jiao J, Lv T, Yao Q Arch Gynecol Obstet. 2022; 307(3):903-917.

PMID: 35713693 DOI: 10.1007/s00404-022-06642-w.

References

Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S . Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol. 2013; 132(3):611-7. DOI: 10.1016/j.ygyno.2013.12.010. View

Aijaz M, Alam K, Maheshwari V, Hakim S, Kamal M . Clinicopathological study of role of CD34 expressions in the stroma of premalignant and malignant lesions of uterine cervix. Ann Diagn Pathol. 2018; 38:87-92. DOI: 10.1016/j.anndiagpath.2018.11.007. View

Kontos C, Christodoulou M, Scorilas A . Apoptosis-related BCL2-family members: Key players in chemotherapy. Anticancer Agents Med Chem. 2013; 14(3):353-74. DOI: 10.2174/18715206113139990091. View

Zhu T, Xu F, Zhang L, Zhang Y, Yang C, Cheng M . Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy. Oncotarget. 2017; 8(60):101087-101094. PMC: 5731857. DOI: 10.18632/oncotarget.19686. View

Tsuchida Y, Therasse P . Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001; 37(1):1-3. DOI: 10.1002/mpo.1154. View

Hu T, Li S, Chen Y, Shen J, Li X, Huang K . Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria. Eur J Cancer. 2012; 48(15):2353-60. DOI: 10.1016/j.ejca.2012.03.015. View

Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S . Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol. 2013; 19(2):348-53. DOI: 10.1007/s10147-013-0559-0. View

Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S . Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018; 36(16):1548-1555. DOI: 10.1200/JCO.2017.75.9985. View

Sun H, Huang K, Tang F, Li X, Wang X, Long S . Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery. Sci Rep. 2018; 8(1):6443. PMC: 5915525. DOI: 10.1038/s41598-018-24413-z. View

10.

Takatori E, Shoji T, Omi H, Kagabu M, Miura F, Takeuchi S . Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol. 2014; 20(2):345-50. DOI: 10.1007/s10147-014-0702-6. View

11.

Bing Z, Jian-ru Y, Yao-quan J, Shi-feng C . Evaluation of angiogenesis in non-small cell lung carcinoma by CD34 immunohistochemistry. Cell Biochem Biophys. 2014; 70(1):327-31. DOI: 10.1007/s12013-014-9916-5. View

12.

Sidney L, Branch M, Dunphy S, Dua H, Hopkinson A . Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014; 32(6):1380-9. PMC: 4260088. DOI: 10.1002/stem.1661. View

13.

Pakalniskis M, Wells W, Schwab M, Froehlich H, Jiang S, Li Z . Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?. Radiology. 2011; 259(2):365-74. PMC: 3079119. DOI: 10.1148/radiol.11100699. View

14.

Maae E, Olsen D, Steffensen K, Jakobsen E, Brandslund I, Sorensen F . Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat. 2012; 133(1):257-65. DOI: 10.1007/s10549-012-1957-0. View

15.

Campbell K, Tait S . Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018; 8(5). PMC: 5990650. DOI: 10.1098/rsob.180002. View

16.

Zhou X, Wang M . Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res. 2015; 14(4):17059-67. DOI: 10.4238/2015.December.16.6. View

17.

Saito T, Takehara M, Tanaka R, Lee R, Horie M, Wataba K . Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol. 2004; 92(1):284-92. DOI: 10.1016/j.ygyno.2003.09.027. View

18.

Moreno-Galindo C, Hermsen M, Garcia-Pedrero J, Fresno M, Suarez C, Rodrigo J . p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2013; 50(2):128-34. DOI: 10.1016/j.oraloncology.2013.10.018. View

19.

Harima Y, Oka A, Nagata K, Harima K, Tanaka Y, Shikata N . [Bax and Bcl-2 expression predict response to radiotherapy in human cervical cancer]. Gan To Kagaku Ryoho. 1998; 25(9):1273-7. View

20.

Ogura T, Tanaka Y, Tamaki H, Harada M . Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Int J Oncol. 2016; 48(6):2330-8. PMC: 4864052. DOI: 10.3892/ijo.2016.3482. View